Elevated serum free light chains predict cardiovascular risk in type 1 diabetes mellitus

British Journal of Diabetes

View Publication Info
 
 
Field Value
 
Title Elevated serum free light chains predict cardiovascular risk in type 1 diabetes mellitus
 
Creator Quinn, Lauren Marie; The Medical School, University of Birmingham, Birmingham, UK
Mcwilliam, Sheridan
Campbell, John P; Clinical Immunology Service, The Medical School, University of Birmingham, Birmingham, UK
Wang, Yan; Clinical Immunology Service, The Medical School, University of Birmingham, Birmingham, UK
Hughes, David; Clinical and Experimental Medicine, Institute of Biomedical Research, The Medical School, University of Birmingham, Birmingham, UK
Drayson, Mark T; Clinical Immunology Service, The Medical School, University of Birmingham, Birmingham, UK
Narendran, Parth; Clinical and Experimental Medicine, Institute of Biomedical Research, The Medical School, University of Birmingham, Birmingham, UK
 
Subject
free light chains, cardiovascular disease, type 1 diabetes mellitus
 
Description Aims: Increased serum polyclonal combined immunoglobulin free light chain (cFLC = FLCκ+FLCλ) has been shown to predict cardiovascular (CV) events in South Asians with type 2 diabetes mellitus. We examined whether cFLC also predicted CV risk in unselected patients with type 1 diabetes mellitus. Methods: cFLC was estimated in the serum of 55 adults with type 1 diabetes mellitus. CV risk was measured through two validated risk engines: Q-Risk and PROCAM. Statistical association was tested using the parametic Pearson’s or the Spearman’s rank correlation coefficient test, Student t-test or Mann-Whitney U-test and Kruskall-Wallis test for parametric or non-parametrically distributed data accordingly. Results: cFLC was associated with CV risk. This association was significant when estimated through either risk engine (PROCAM p=0.003, Q-Risk p=0.012). cFLC was associated with diabetes mellitus duration (p=0.003), age (p=0.006) and history of cardiac disease (p=0.042). Conclusions: These findings indicate that cFLC is a marker of CV risk in people with type 1 diabetes mellitus. Moreover, it supports emerging data demonstrating cFLC as a prognostic indicator for mortality.
 
Publisher ABCD (Diabetes Care) Ltd
 
Contributor
 
Date 2016-12-20
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

 
Format text/html
application/pdf
 
Identifier http://www.bjd-abcd.com/index.php/bjd/article/view/203
10.15277/bjd.2016.107
 
Source British Journal of Diabetes; Vol 16, No 4 (2016); 176-178
2397-6241
2397-6233
 
Language eng
 
Relation http://www.bjd-abcd.com/index.php/bjd/article/view/203/343
http://www.bjd-abcd.com/index.php/bjd/article/view/203/344
 
Coverage


 
Rights Copyright (c) 2016 British Journal of Diabetes
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2016 Simon Fraser University Library